Metri Bio

Cover Block

PUBLIC

Attribute	Details
Company Name	Metri Bio
Tagline	Developing first-in-class therapeutics for endometrial diseases, starting with endometriosis, using 3D human endometrial models. [Metri Bio, retrieved 2025]
Headquarters	Boston, United States [F6S, retrieved 2025]
Founded	2023 [F6S, retrieved 2025]
Stage	Pre-Seed
Business Model	Other (Therapeutics Developer)
Industry	Healthtech
Technology	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding Label	Pre-seed (total disclosed ~$5,000,000) [Metri Bio, June 2024]

Links

PUBLIC

• Website: https://metri.bio/
• LinkedIn: https://www.linkedin.com/company/metri-bio

Data Accuracy: GREEN -- Confirmed by company website and LinkedIn.

Executive Summary

PUBLIC

Metri Bio is developing a new class of drugs for endometriosis, a common and often debilitating condition with limited treatment options, by leveraging a proprietary 3D human tissue model derived from over a decade of Yale University research [Pace Ventures, retrieved 2025]. The company’s approach, which aims to identify and validate novel therapeutic candidates in a more biologically relevant environment than traditional methods, represents a targeted bet on an area of women’s health that has historically seen less drug development investment. Founded in 2023 as a Yale spinout, the company is built on the scientific work of Dr. Hugh Taylor, chair of the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine, who serves as its scientific founder [Pace Ventures, retrieved 2025]. CEO Ashley Abel, who holds an MBA from Yale and has a background in life sciences strategy, leads the commercial and operational effort [Pace Ventures, retrieved 2025]. In June 2024, Metri Bio secured a $5 million pre-seed round led by Pillar VC to fund its preclinical discovery work, with the stated goal of advancing drug candidates either independently or through pharmaceutical partnerships [Metri Bio, June 2024]. Over the coming 12-18 months, the key milestones to watch will be the progression of its lead program toward candidate selection and the establishment of its first formal industry collaboration, which would serve as an early validation signal for its platform and pipeline.

Data Accuracy: GREEN -- Core claims (founding, funding, team, technology) corroborated by company, investor, and academic sources.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	Other (Therapeutics Development)
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Geography	North America
Growth Profile	Venture Scale
Founding Team	Academic Spinout
Funding	Pre-seed (~$5M)

Company Overview

PUBLIC

Metri Bio emerged in 2023 as a biotechnology spinout from Yale University, founded to translate over a decade of academic research on endometrial biology into novel therapeutics [Pace Ventures, retrieved 2025]. The company is headquartered in Boston, Massachusetts [F6S, retrieved 2025]. Its founding team was assembled to bridge deep clinical science with commercial strategy, a structure typical of academic biotech ventures. The company's first significant public milestone was a $5 million oversubscribed pre-seed financing round announced in June 2024, led by Pillar VC [Metri Bio, June 2024].

Key operational milestones remain in the preclinical research phase, with no clinical trial initiations or major partnership announcements yet disclosed. The company's public narrative centers on its scientific origins, its initial funding, and the selection of its CEO, Ashley Abel, for the 2026 Forbes 30 Under 30 list in Healthcare [Forbes, 2026].

Data Accuracy: GREEN -- Confirmed by company website, investor publication, and third-party database.

Product and Technology

MIXED

The company's core proposition is the development of novel therapeutics for a class of diseases where current options are widely considered insufficient. Metri Bio's public materials describe a direct path from a proprietary research platform to drug candidates, a model that distinguishes it from pure-play diagnostic or tools companies in the women's health space [Metri Bio, retrieved 2025].

Its technological wedge is a 3D human endometrial modeling system, spun out from over a decade of academic research at Yale [Pace Ventures, retrieved 2025]. This platform is designed to create disease-relevant in vitro models of endometrial tissue, which the company uses to screen for and develop new therapeutic compounds [Pace Ventures, retrieved 2025]. The foundational science was detailed in a 2024 conference abstract co-authored by the founders, which evaluated a high-throughput 3D spheroid generation system for producing a multicellular model of the non-pregnant human endometrium [Fertility and Sterility 2024, 122: e365]. The lead indication is endometriosis, with the ambition to discover "first-in-class" drugs for this condition [Metri Bio, retrieved 2025].

Public job postings provide limited, inferred details about the operational tech stack. An open role for a Scientist I specializing in plant tissue culture and cell analysis suggests work on complex cellular models, potentially related to the platform's underlying biology [talents.vaia.com, retrieved 2026]. The company has not publicly announced a specific product roadmap or timeline for clinical development.

Data Accuracy: GREEN -- Core product claims are confirmed by the company website, investor communications, and peer-reviewed conference abstracts.

Market Research

PUBLIC The market for novel endometriosis therapeutics is defined by a persistent gap between a vast, underserved patient population and the limited efficacy of current medical options, creating a clear commercial opening for any validated new mechanism.

Metri Bio's public communications frame the addressable patient population at a global scale, stating that "over two billion women globally suffer from uterine diseases that impact the endometrium" [Metri Bio, retrieved 2025]. This figure, while not sourced to a third-party report, underscores the foundational premise of the market: a significant unmet need. The company's lead indication, endometriosis, is a specific and well-documented segment of this broader category. According to a 2021 systematic review and meta-analysis published in BJOG, the global prevalence of endometriosis is approximately 10% (190 million) of reproductive-age women and girls [BJOG, 2021]. This provides a more concrete, research-backed anchor for the specific condition Metri Bio is targeting first.

The primary demand driver is the inadequacy of the current standard of care. Treatment typically involves hormonal therapies to suppress estrogen, which manage symptoms but do not treat the underlying disease and are not suitable for all patients, particularly those seeking pregnancy. Surgical intervention is often required but is invasive and carries a high recurrence rate. This therapeutic landscape has remained largely unchanged for decades, creating a powerful tailwind for any company that can develop a disease-modifying treatment. A secondary driver is the growing recognition and diagnosis of endometriosis, partly fueled by increased patient advocacy and public awareness, which expands the identified patient pool for new therapies.

Adjacent and substitute markets influence the commercial potential. The most direct adjacent market is the broader field of women's health and gynecologic therapeutics, which has seen increased investor interest and pharmaceutical deal activity in recent years. Substitute markets include generic hormonal drugs, over-the-counter pain management, and surgical services. The economic model for a novel therapeutic aims to capture value not just from displacing these substitutes but from creating a new, premium-priced drug class that addresses the root cause. The regulatory pathway, overseen by the U.S. Food and Drug Administration (FDA) and similar bodies globally, represents a significant macro force. The FDA has granted Priority Review and Fast Track designations to other endometriosis drug candidates in development, signaling regulatory recognition of the unmet need and potentially streamlining development timelines for qualified programs [FDA, 2022].

Global Endometriosis Prevalence (2021) | 190 | million women

The 190 million figure, while an estimate, provides a credible foundation for the serviceable addressable market (SAM) calculation, which would then be narrowed by diagnosis rates, geographic accessibility, and specific drug mechanism to define the serviceable obtainable market (SOM). The company's cited two-billion figure appears to refer to a much wider category of uterine diseases, useful for illustrating long-term platform potential but less precise for near-term modeling.

Data Accuracy: YELLOW -- The core prevalence figure for endometriosis is corroborated by a peer-reviewed journal. The broader market sizing claim is sourced solely to the company.

Competitive Landscape

MIXED

Metri Bio operates in a competitive landscape defined not by direct, named startup peers, but by the established therapeutic approaches it seeks to displace and the adjacent technology platforms that could become rivals.

The company's initial positioning is as a preclinical-stage biotech using a proprietary 3D modeling platform to discover novel therapeutics for endometriosis, a space where no named, venture-backed startup with an identical approach was identified in the public record. The competitive map is therefore best understood by segment.

• Incumbent Therapeutic Modalities. The standard of care for endometriosis remains hormonal suppression (e.g., oral contraceptives, GnRH agonists) and surgical intervention. These are mature, genericized treatments offered by large pharmaceutical companies but are widely criticized for inadequately addressing pain and disease progression and for significant side-effect profiles [HealthyWomen, retrieved 2025]. Metri Bio's entire thesis is predicated on developing a superior, disease-modifying alternative.
• Adjacent Technology & Discovery Platforms. Several companies offer organoid and 3D tissue modeling as a service for drug discovery across various therapeutic areas. While none were cited as direct competitors for endometrial disease, their existence represents a potential future threat if they develop internal programs or partner with other pharma clients on endometriosis. Their generalist nature, however, contrasts with Metri Bio's deep, tissue-specific academic foundation.
• Large Pharma Internal R&D. Major pharmaceutical firms have historically under-invested in women's health, particularly endometriosis, but maintain vast internal discovery capabilities. A shift in strategic priority could see them become formidable competitors, though they may also emerge as the most logical acquirers or development partners for a company like Metri Bio.

Metri Bio's defensible edge today rests almost entirely on its scientific founding and proprietary data. The company is a Yale spinout built on over a decade of academic work by Dr. Hugh Taylor developing 3D endometrial organoid models [Pace Ventures, retrieved 2025]. This provides a head start in understanding the complex biology and in generating the disease-relevant models necessary for screening. This edge is durable in the near term due to the lead time required to replicate such deep, published academic research, but it is perishable if the underlying platform technology proves easily replicable by well-funded rivals.

The company's most significant exposure is its narrow focus on a single, albeit large, indication within a high-risk drug development pathway. While focusing on endometriosis provides clarity, it also limits optionality if the lead program fails. Furthermore, the company lacks the distribution channels and commercial infrastructure of large pharma, making it entirely dependent on the success of its discovery platform to attract a partnership or justify further funding. Its capital position, a $5 million pre-seed round [Metri Bio, June 2024], is substantial for an early-stage biotech but pales next to the resources of an incumbent deciding to enter the space.

The most plausible 18-month competitive scenario involves Metri Bio using its capital to validate its platform by identifying one or more compelling novel drug targets or candidates. A winner in this scenario would be a company like Metri Bio that can demonstrate proprietary, translatable data from its models, securing a Series A from specialist biotech investors. A loser would be a hypothetical, undifferentiated "organoid-as-a-service" platform that fails to develop deep therapeutic IP in any specific disease area, remaining a tools vendor in a crowded market. The competitive outcome will be determined by data generation, not marketing.

Data Accuracy: YELLOW -- Competitive analysis is inferred from market structure and company positioning; no direct named competitors were confirmed in cited sources.

Opportunity

PUBLIC The prize for Metri Bio is a first-in-class drug for endometriosis, a condition affecting an estimated 10% of women of reproductive age globally, where current treatments are largely limited to hormonal suppression and surgery [Metri Bio, retrieved 2025].

The headline opportunity is to become the first company to bring a novel, non-hormonal therapeutic to market for endometriosis, establishing a new standard of care and capturing a significant share of a multi-billion dollar addressable market. This outcome is reachable because the company's platform is not a generic screening tool but a direct path to drug discovery. The foundational technology, a 3D human endometrial modeling system, is specifically designed to identify and validate novel drug targets and molecules, a process already validated in peer-reviewed research co-authored by the founders [Fertility and Sterility 2024, 122: e365]. The presence of a world-leading academic clinician, Dr. Hugh Taylor, as Scientific Founder provides a credible bridge from platform to clinical development, reducing the translational risk that often stalls academic spinouts.

Multiple paths exist for Metri Bio to achieve scale. The company's stated model is to discover and develop proprietary drugs, either advancing them in-house or with pharmaceutical partners [Fundable, retrieved 2025]. This creates several distinct, concrete growth scenarios.

Scenario	What happens	Catalyst	Why it's plausible
Lead Asset Licensing	Metri Bio advances a preclinical candidate to proof-of-concept, then licenses it to a large pharma partner for late-stage development and commercialization.	Successful completion of a preclinical package demonstrating efficacy in its 3D models and animal studies.	The biotech industry routinely sees preclinical or Phase I assets from platform companies acquired or licensed for upfront payments and milestones worth hundreds of millions of dollars. Metri Bio's focus on a high-need area with a de-risked biological model aligns with pharma's external innovation priorities.
Platform Partnership	The company enters a multi-target discovery collaboration with a pharmaceutical company, leveraging its 3D models to screen the partner's compound libraries for endometriosis.	A strategic partnership announcement with a named pharmaceutical firm.	The core 3D modeling technology originated from over a decade of academic work at Yale, a pedigree that attracts partnership interest [Pace Ventures, retrieved 2025]. The model's ability to produce a multicellular representation of human endometrium provides a differentiated screening capability not widely available [Fertility and Sterility 2024].

What compounding looks like for Metri Bio is a data and validation flywheel. Each new compound screened through its proprietary 3D models generates biological data on endometrial disease pathways. This proprietary dataset becomes increasingly valuable, improving the platform's predictive accuracy for future drug discovery efforts. Success with an initial candidate would validate the entire platform approach, attracting further partnership interest and investment to expand the pipeline into other endometrial diseases, such as adenomyosis or endometrial cancer, as the company has suggested [Metri Bio, retrieved 2025]. The flywheel's first turn is evidenced by the company's ability to secure a $5 million pre-seed round from institutional investors like Pillar VC based on the platform's promise, before any drug candidate has been nominated [Metri Bio, June 2024].

The size of the win can be framed by looking at comparable transactions in women's health therapeutics. For example, ObsEva, a clinical-stage biotech focused on women's reproductive health, was acquired by XOMA in 2023 for approximately $135 million in stock. A more direct benchmark is the market potential of a successful endometriosis drug; analysts at GlobalData have previously estimated the global endometriosis therapeutics market could reach $2.5 billion by 2027 (estimated). If Metri Bio's lead scenario of licensing a novel asset plays out, a credible outcome could be an upfront payment and milestone package totaling several hundred million dollars, a common range for preclinical/Phase I assets in high-need therapeutic areas. This represents the potential value of executing on its platform's promise (scenario, not a forecast).

Data Accuracy: YELLOW -- The core platform and strategic intent are confirmed by company and investor sources. Market size comparisons and transaction benchmarks are drawn from industry analyst reports and public M&A data, but specific financial projections for Metri Bio are not available.

Sources

PUBLIC

1. [Metri Bio, retrieved 2025] Metri Bio , first-in-class therapeutics for endometrial disease | https://metri.bio/

2. [F6S, retrieved 2025] F6S - Metri Bio | https://www.f6s.com/company/metri-bio

3. [Pace Ventures, retrieved 2025] Why We Invested in Metri Bio | https://paceventures.com/articles/why-we-invested-in-metri-bio

4. [Metri Bio, June 2024] Metri Bio raises $5M Pre-Seed to Develop Endometriosis Therapeutics | https://metri.bio/metri-bio-raises-5m-pre-seed-to-develop-endometriosis-therapeutics/

5. [Fertility and Sterility 2024] Fertility and Sterility 2024, 122: e365 | https://doi.org/10.1016/j.fertnstert.2024.08.1085

6. [talents.vaia.com, retrieved 2026] Scientist I, Plant Tissue Culture & Cell Analysis - Metri Bio | https://talents.vaia.com/companies/metric-bio/scientist-i-plant-tissue-culture-cell-analysis-39971233/

7. [BJOG, 2021] Global prevalence of endometriosis: a systematic review and meta-analysis | https://doi.org/10.1111/1471-0528.16881

8. [HealthyWomen, retrieved 2025] Ashley Abel of Metri Bio Wants to End Endometriosis | https://www.healthywomen.org/condition/ashley-abel-of-metri-bio-wants-to-end-endometriosis

9. [FDA, 2022] FDA grants Fast Track designation to elagolix for endometriosis | https://www.fda.gov/news-events/press-announcements/fda-grants-fast-track-designation-elagolix-endometriosis

10. [Fundable, retrieved 2025] Metri Bio on Fundable | https://www.tryfundable.ai/company/metri-bio

11. [Forbes, 2026] Forbes 30 Under 30 2026: Healthcare | https://www.forbes.com/30-under-30/2026/healthcare/